血液培養検査市場 : 2028年までの世界予測

Report Overview

The global blood culture tests is projected to reach USD 7.6 billion by 2028 from USD 5.2 billion in 2023, at a CAGR of 8.0% during the forecast period. Growth in this market is majorly driven by the rising geriatric population, growing incidence of sepsis cases and high cost treatment, high incidence of blood stream infections, growing demand for rapid diagnostic techniques and high prevalence of infectious diseases. However, high cost of automated instruments and lack of trained laboratory technicians are expected to restrain the market growth in the upcoming years.

The automated blood culture tests segment is projected to grow at the highest CAGR during the forecast period.

Based on method, the market for blood culture tests is divided into segments for automated blood culture method and conventional/manual blood culture method. The automated blood culture tests segment is projected to grow at the highest CAGR during the forecast period. Key factors driving revenue growth for automated blood culture equipment is the ability to expedite infection identification and treatment, quick turnaround time and reduced risk of contamination due to low manual intervention. Consequently, timely identification allows for prompt initiation of targeted treatments, leading to improved patient outcomes and shorter hospital stays.

The consumables segment is the largest share of the market during the forecast period.

Based on product, the blood culture tests is broadly segmented into, instruments, consumables, and software and services. The consumables segment accounted for the largest share and this is attributed to the repeated purchase of media for the detection of yeast, bacteria and fungi and increase in drug-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamase (ESBL)-producing bacteria.

The molecular technology segment accounted for the second largest share of the market.

Based on technology, the blood culture tests is broadly segmented into proteomics, culture-based technologies and molecular technologies. Due to its largest and fastest growing segment which is the microarray segment, the molecular technologies market is accounted for the second largest share of the blood culture tests market. This can be attributed to the increasing incidence of sepsis, which demands rapid diagnostic techniques for detecting the presence of bacteria, fungi, and mycobacteria from blood samples.

The bacteremia segment accounted for the largest share of the market.

Based on applications, the blood culture tests is broadly segmented into mycobacterial detection, bacteremia and fungemia. Bacteremia segment has accounted for the largest share of the blood culture tests market. The main reason for this is the increasing number of bloodstream infections and the growing number of sepsis cases worldwide. Sepsis and septic shock is associated with a high morbidity rate (which can result in a prolonged hospital stay and increase the associated healthcare costs) and mortality rate. Patients with implanted devices; endotracheal tubes; chronic healthcare conditions such as diabetes, cancer, and diseases of the kidney and liver; and those with suppressed immune systems are more prone to developing sepsis.

The reference laboratories segment is projected to have the highest CAGR.
Based on end users, the bloodculture tests market is divided into academic research laboratories, hospital laboratories, reference laboratories, and other laboratories (involves independent research laboratories, pathology laboratories, bacteriological laboratories, and physician office laboratories (POLs). The reference laboratories segment is projected to grow at the highest rate in this market. This is due to the increasing outsourcing of blood culture tests by hospitals to reference laboratories.

Europe accounted for the second largest share of the blood culture tests market.

Europe accounted for the second largest share of the blood culture tests . Growth in the European market is driven by the increasing number of sepsis cases, high healthcare expenditure, rapidly growing geriatric population, growing regulatory approvals, and strong government support in this region. Healthcare costs have risen exponentially in Europe, and various initiatives to raise funds to cover healthcare costs have proven inadequate.

The break-up of the profile of primary participants in the blood culture tests market:
• By Company Type: Tier 1- 60%, Tier 2- 30%, and Tier 3- 10%
• By Designation: C-Level Executives- 50%, Directors-40%, and Others-10%
• By Region: North America- 45% , Europe- 35%, Asia-Pacific- 15%, and Rest of the World- 5%

Key players in the Blood culture tests
The key players operating in the blood culture tests include Danaher (US), Luminex Corporation (US), Bruker (US), Roche Diagnostics (Switzerland), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Terumo Corporation (Japan), Becton, Dickinson and Company (US), BioMérieux (France), Himedia Laboratories Pvt. Ltd. (India), Autobio Diagnostics Co., Ltd. (China), Axiom Laboratories (India), Mikroscan Technologies, Inc. (US), Labotronics Ltd. (UK), Hardy Diagnostics (US), OpGen, Inc. (US), Meditech Technologies India Private Limited (India), Iridica (US), Thermo Fisher Scientific Inc. (US), Biosystems, Inc (US), BINDER GmBH (Germany), Biobase Biotech (Jinan) Co., Ltd. (China), Scenker Biological Technology Co., Ltd. (China), Bulldog Bio (England), and Anaerobe Systems, Inc. (US).

Research Coverage:
The report analyzes the blood culture tests and aims at estimating the market size and future growth potential of this market based on various segments such as method, product, technology, application, end user, and region. The report also includes a product portfolio matrix of various blood culture tests products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Analysis of Key drivers (growing incidences of sepsis cases and high cost of treatment, rising geriatric population, high incidence of bloodstream infections, growing demand for rapid diagnostic techniques, and the high prevalence of infectious diseases), restraints (high cost of automated instruments and lack of trained laboratory technicians are limiting the growth of this market), opportunities (growth opportunities in emerging economies, identification of antibiotic resistance microorganisms), and challenges ( market cannibalization, survival of new entrants).
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global blood culture tests . The report analyzes this market by. method, product, technology, application, end user.
• Service Enhancement/Innovation: Detailed insights on upcoming trends in the global blood culture tests.
• Market Development: Comprehensive information on the lucrative emerging markets by method, product, technology, application, end user.
• Market Diversification: Exhaustive information about new services or service enhancements, growing geographies, recent developments, and investments in the global blood culture tests.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global blood culture tests.

Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS AND EXCLUSIONS 40
1.3 MARKET SCOPE 41
1.3.1 MARKETS COVERED 41
1.3.2 REGIONS COVERED 42
1.4 YEARS CONSIDERED 42
1.5 CURRENCY CONSIDERED 42
TABLE 1 STANDARD CURRENCY CONVERSION RATES 43
1.6 STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 43
1.8 IMPACT OF RECESSION: BLOOD CULTURE TESTS MARKET 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH APPROACH 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Key data from secondary sources 46
2.1.2 PRIMARY DATA 47
FIGURE 2 PRIMARY SOURCES 47
2.1.2.1 Key data from primary sources 48
2.1.2.2 Insights from primary experts 48
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 49
2.2 MARKET SIZE ESTIMATION 49
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 50
FIGURE 5 SEGMENTAL EXTRAPOLATION: GLOBAL BLOOD CULTURE TESTS MARKET (2022) 50
FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 52
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
2.3 APPROACH TO DETERMINE IMPACT OF ECONOMIC RECESSION 53
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 54
FIGURE 8 MARKET DATA TRIANGULATION METHODOLOGY 54
2.5 MARKET SHARE ANALYSIS 55
2.6 STUDY ASSUMPTIONS 55
2.7 RESEARCH LIMITATIONS 55
2.7.1 METHODOLOGY-RELATED LIMITATIONS 55
2.7.2 SCOPE-RELATED LIMITATIONS 55
2.8 RISK ASSESSMENT 56
TABLE 2 RISK ASSESSMENT: BLOOD CULTURE TESTS MARKET 56
3 EXECUTIVE SUMMARY 57
FIGURE 9 BLOOD CULTURE TESTS MARKET, BY METHOD, 2023 VS. 2028 (USD MILLION) 57
FIGURE 10 BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 58
FIGURE 11 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 58
FIGURE 12 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 59
FIGURE 13 BLOOD CULTURE TESTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 59
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF BLOOD CULTURE TESTS MARKET 60
4 PREMIUM INSIGHTS 61
4.1 BLOOD CULTURE TESTS MARKET OVERVIEW 61
FIGURE 15 GROWING INCIDENCE OF SEPSIS CASES AND HIGH COST OF TREATMENT TO DRIVE MARKET 61
4.2 BLOOD CULTURE TESTS MARKET, BY PRODUCT 62
FIGURE 16 CONSUMABLES SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 62
4.3 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD AND COUNTRY (2022) 62
FIGURE 17 CONVENTIONAL/MANUAL BLOOD CULTURE SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC BLOOD CULTURE TESTS MARKET IN 2022 62
4.4 BLOOD CULTURE TESTS MARKET: REGIONAL MIX 63
FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD 63
4.5 BLOOD CULTURE TESTS MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
FIGURE 20 BLOOD CULTURE TESTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
5.1.1 DRIVERS 65
5.1.1.1 Increasing number of sepsis patients and rising cost of treatment 65
TABLE 3 US: FIVE MOST EXPENSIVE CONDITIONS TREATED IN HOSPITALS 65
5.1.1.2 Rapid growth in geriatric population with chronic diseases 65
TABLE 4 GERIATRIC POPULATION: KEY STATISTICS 66
5.1.1.3 High incidence of nosocomial bloodstream infections 66
5.1.1.4 Growing demand for rapid diagnostic techniques with faster turnaround times 66
5.1.1.5 High prevalence of infectious diseases globally 67
5.1.2 RESTRAINTS 68
5.1.2.1 High cost of automated blood culture instruments 68
5.1.2.2 Lack of trained laboratory technicians 68
5.1.3 OPPORTUNITIES 68
5.1.3.1 Growth opportunities in emerging economies 68
5.1.3.2 Increased need to identify antibiotic-resistant microorganisms 69
5.1.4 CHALLENGES 69
5.1.4.1 Market cannibalization for conventional products 69
5.1.4.2 Difficulty in survival of new entrants 69
5.2 INDUSTRY TRENDS 70
5.2.1 LABORATORY AUTOMATION FOR INCREASED EFFICIENCY AND ACCURATE DIAGNOSIS 70
5.2.2 FOCUS ON ANTIMICROBIAL STEWARDSHIP 70
5.3 TECHNOLOGY ANALYSIS 71
5.3.1 ADVANCED FLUORESCENCE DETECTION TECHNOLOGY 71
5.4 AVERAGE SELLING PRICE, BY TYPE 71
5.4.1 AVERAGE SELLING PRICE FOR BLOOD CULTURE TEST PRODUCTS, BY KEY PLAYER (2022) 72
TABLE 5 REGIONAL PRICING ANALYSIS OF BLOOD CULTURE TEST PRODUCTS, BY TYPE, 2021 (USD) 72
5.5 VALUE CHAIN ANALYSIS 73
FIGURE 21 MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 73
5.6 SUPPLY CHAIN ANALYSIS 74
FIGURE 22 SUPPLY CHAIN ANALYSIS: BLOOD CULTURE TESTS MARKET 74
5.7 ECOSYSTEM MAPPING 75
FIGURE 23 ECOSYSTEM MAPPING: BLOOD CULTURE TESTS MARKET 75
5.8 PORTER’S FIVE FORCES ANALYSIS 75
TABLE 6 PORTER’S FIVE FORCES ANALYSIS: BLOOD CULTURE TESTS MARKET 75
5.8.1 THREAT OF NEW ENTRANTS 76
5.8.2 THREAT OF SUBSTITUTES 76
5.8.3 BARGAINING POWER OF BUYERS 76
5.8.4 BARGAINING POWER OF SUPPLIERS 76
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.9 TARIFF AND REGULATORY ANALYSIS 77
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
TABLE 7 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77
5.9.2 REGULATORY ANALYSIS 77
5.9.2.1 North America 77
5.9.2.1.1 US 77
TABLE 8 US FDA: MEDICAL DEVICE CLASSIFICATION 78
TABLE 9 US: TIME, COST, AND COMPLEXITY OF REGISTRATION 78
5.9.2.1.2 Canada 78
TABLE 10 CANADA: CLASSIFICATION OF PRODUCTS 78
TABLE 11 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION 79
5.9.2.2 Europe 79
TABLE 12 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES 79
5.9.3 ASIA PACIFIC 80
5.9.3.1 Japan 80
5.9.3.2 China 80
5.9.3.3 India 80
5.10 PATENT ANALYSIS 81
5.10.1 PATENT PUBLICATION TRENDS FOR BLOOD CULTURE TESTS MARKET 81
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011–JUNE 2023) 81
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 81
FIGURE 25 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR BLOOD CULTURE TEST PATENTS (JANUARY 2011–JUNE 2023) 82
FIGURE 26 TOP APPLICANTS FOR BLOOD CULTURE TEST PATENTS (COUNTRY/REGION) (JANUARY 2011–JULY 2023) 82
TABLE 13 BLOOD CULTURE TESTS MARKET: LIST OF PATENTS (2020–2023) 83
5.11 KEY CONFERENCES AND EVENTS IN 2023–2024 84
TABLE 14 BLOOD CULTURE TESTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023–2024 84
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 85
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS IN BLOOD CULTURE TESTS MARKET 85
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS IN BLOOD CULTURE TESTS MARKET (%) 85
5.12.2 BUYING CRITERIA 86
FIGURE 28 KEY BUYING CRITERIA FOR BLOOD CULTURE TEST METHODS 86
TABLE 16 KEY BUYING CRITERIA FOR BLOOD CULTURE TEST METHODS 86
6 BLOOD CULTURE TESTS MARKET, BY METHOD 87
6.1 INTRODUCTION 88
TABLE 17 BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 88
6.2 CONVENTIONAL/MANUAL BLOOD CULTURE 88
6.2.1 CONVENTIONAL/MANUAL BLOOD CULTURE METHOD TO ACCOUNT FOR LARGER SHARE OF BLOOD CULTURE TESTS MARKET 88
TABLE 18 EXAMPLES OF CONVENTIONAL/MANUAL BLOOD CULTURE PRODUCTS 89
TABLE 19 BLOOD CULTURE TESTS MARKET FOR CONVENTIONAL/MANUAL BLOOD CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 90
6.3 AUTOMATED BLOOD CULTURE 90
6.3.1 INCREASED R&D INVESTMENTS BY MANUFACTURERS FOR DEVELOPING NOVEL PRODUCTS TO DRIVE MARKET 90
TABLE 20 EXAMPLES OF AUTOMATED BLOOD CULTURE PRODUCTS 91
TABLE 21 BLOOD CULTURE TESTS MARKET FOR AUTOMATED BLOOD CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 92
7 BLOOD CULTURE TESTS MARKET, BY PRODUCT 93
7.1 INTRODUCTION 94
TABLE 22 BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 94
7.2 CONSUMABLES 94
TABLE 23 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 94
TABLE 24 BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY COUNTRY, 2021–2028 (USD MILLION) 95
7.2.1 BLOOD CULTURE MEDIA 95
TABLE 25 EXAMPLES OF BLOOD CULTURE MEDIA 96
TABLE 26 BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 96
TABLE 27 BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
7.2.1.1 Aerobic blood culture media 97
7.2.1.1.1 Aerobic blood culture media to be fastest-growing segment of blood culture media market during forecast period 97
TABLE 28 AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
7.2.1.2 Pediatric aerobic blood culture media 98
7.2.1.2.1 Increased need to recover pathogens from bloodstream of children to drive segment 98
TABLE 29 PEDIATRIC AEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 99
7.2.1.3 Anaerobic blood culture media 99
7.2.1.3.1 Increased need for routine diagnosis of bacteria in blood culture to drive segment 99
TABLE 30 ANAEROBIC BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
7.2.1.4 Mycobacterial blood culture media 100
7.2.1.4.1 Rising prevalence of tuberculosis to drive segment 100
TABLE 31 MYCOBACTERIAL BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
7.2.1.5 Fungi/yeast blood culture media 101
7.2.1.5.1 Easy identification and characterization of special fungal species to drive segment 101
TABLE 32 FUNGI/YEAST BLOOD CULTURE MEDIA MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.2.2 ASSAY KITS & REAGENTS 102
7.2.2.1 Increased need for rapid identification of bacteria and yeast from positive blood cultures to drive market 102
TABLE 33 EXAMPLES OF BLOOD CULTURE ASSAY KITS & REAGENTS 103
TABLE 34 ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
7.2.3 BLOOD CULTURE ACCESSORIES 104
7.2.3.1 Growing number of blood culture tests to drive market 104
TABLE 35 EXAMPLES OF BLOOD CULTURE ACCESSORIES 104
TABLE 36 BLOOD CULTURE ACCESSORIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
7.3 INSTRUMENTS 105
TABLE 37 BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 106
7.3.1 AUTOMATED BLOOD CULTURE SYSTEMS 106
7.3.1.1 Need for automated imaging systems and advanced algorithms to drive market 106
TABLE 38 EXAMPLES OF AUTOMATED BLOOD CULTURE SYSTEMS 107
TABLE 39 AUTOMATED BLOOD CULTURE SYSTEMS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
7.3.2 SUPPORTING LABORATORY EQUIPMENT 108
TABLE 40 SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 41 SUPPORTING LABORATORY EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
7.3.2.1 Incubators 109
7.3.2.1.1 Incubators to provide optimal environment with adequate temperature and oxygen levels for microbial growth 109
TABLE 42 INCUBATORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
7.3.2.2 Colony counters 110
7.3.2.2.1 Colony counters to increase direct image scanning and analysis capability 110
TABLE 43 COLONY COUNTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
7.3.2.3 Microscopes 111
7.3.2.3.1 Favorable funding scenario for R&D and technological advancements to drive segment 111
TABLE 44 MICROSCOPES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
7.3.2.4 Gram stainers 112
7.3.2.4.1 Gram strainers to guide initial antibiotic section and appropriate empirical therapy 112
TABLE 45 GARAM STAINERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
7.4 SOFTWARE & SERVICES 113
7.4.1 INCREASED NEED FOR AUTOMATED SYSTEMS IN HOSPITAL-BASED LABORATORIES TO DRIVE MARKET 113
TABLE 46 BLOOD CULTURE TESTS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 114
8 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY 115
8.1 INTRODUCTION 116
TABLE 47 BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 116
8.2 CULTURE-BASED TECHNOLOGIES 116
8.2.1 DRAWBACKS ASSOCIATED WITH TRADITIONAL CULTURE-BASED TECHNOLOGIES TO LIMIT MARKET 116
8.3 TOP OF FORM 117
TABLE 48 BLOOD CULTURE TESTS MARKET FOR CULTURE-BASED TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 117
8.3.1 MOLECULAR TECHNOLOGIES 117
TABLE 49 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 50 BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 119
8.3.2 MICROARRAYS 119
8.3.2.1 Determination of better genotyping characterization and identification of bacterial infections to drive segment 119
TABLE 51 MICROARRAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 120
8.3.3 PCR 120
8.3.3.1 Reduced risk of contaminations and easy detection of bloodstream infections to drive segment 120
TABLE 52 PCR MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
8.3.4 PNA-FISH 121
8.3.4.1 PNA-FISH to use genetic markers for analysis of pathogens directly from whole blood samples 121
TABLE 53 PNA-FISH MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8.4 PROTEOMICS 122
8.4.1 PROTEOMICS TO CONTROL INFECTIOUS DISEASES AND ANALYZE COMPLEX MICROBIAL SYSTEMS WITHIN HUMAN FLUIDS 122
TABLE 54 BLOOD CULTURE TESTS MARKET FOR PROTEOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 55 EXAMPLES OF MALDI-TOF MS SYSTEMS 124
9 BLOOD CULTURE TESTS MARKET, BY APPLICATION 125
9.1 INTRODUCTION 126
TABLE 56 BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028(USD MILLION) 126
9.2 BACTEREMIA 126
9.2.1 GROWING INCIDENCE OF SEPSIS CASES GLOBALLY TO DRIVE MARKET 126
TABLE 57 BLOOD CULTURE TESTS MARKET FOR BACTEREMIA, BY COUNTRY, 2021–2028 (USD MILLION) 127
9.3 FUNGEMIA 127
9.3.1 INCREASING INCIDENCE OF BLOODSTREAM INFECTIONS TO DRIVE MARKET 127
TABLE 58 BLOOD CULTURE TESTS MARKET FOR FUNGEMIA, BY COUNTRY, 2021–2028 (USD MILLION) 128
9.4 MYCOBACTERIAL DETECTION 128
9.4.1 RISING GERIATRIC POPULATION WITH TUBERCULOSIS TO DRIVE MARKET 128
TABLE 59 BLOOD CULTURE TESTS MARKET FOR MYCOBACTERIAL DETECTION, BY COUNTRY, 2021–2028 (USD MILLION) 129
10 BLOOD CULTURE TESTS MARKET, BY END USER 130
10.1 INTRODUCTION 131
TABLE 60 BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 131
10.2 HOSPITAL LABORATORIES 131
10.2.1 INCREASED ABILITY TO CONDUCT LARGE VOLUME OF BLOOD CULTURE TESTS TO DRIVE MARKET 131
TABLE 61 BLOOD CULTURE TESTS MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 132
10.3 REFERENCE LABORATORIES 133
10.3.1 INCREASING REQUIREMENT OF ROUTINE AND SPECIALTY TESTS TO DRIVE MARKET 133
TABLE 62 BLOOD CULTURE TESTS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 134
10.4 ACADEMIC RESEARCH LABORATORIES 134
10.4.1 INCREASING FOCUS ON R&D OF INNOVATIVE TESTS FOR BLOODSTREAM INFECTIONS TO DRIVE MARKET 134
TABLE 63 BLOOD CULTURE TESTS MARKET FOR ACADEMIC RESEARCH LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 135
10.5 OTHER LABORATORIES 135
TABLE 64 BLOOD CULTURE TESTS MARKET FOR OTHER LABORATORIES, BY COUNTRY, 2021–2028 (USD MILLION) 136
11 BLOOD CULTURE TESTS MARKET, BY REGION 137
11.1 INTRODUCTION 138
TABLE 65 BLOOD CULTURE TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 138
11.2 NORTH AMERICA 138
FIGURE 29 NORTH AMERICA: BLOOD CULTURE TESTS MARKET SNAPSHOT 139
TABLE 66 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 67 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 140
TABLE 68 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 140
TABLE 69 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 70 NORTH AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 71 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 72 NORTH AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 141
TABLE 73 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 142
TABLE 74 NORTH AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 142
TABLE 75 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 142
TABLE 76 NORTH AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 143
11.2.1 US 143
11.2.1.1 US to dominate blood culture tests market during study period 143
TABLE 77 US: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 144
TABLE 78 US: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 144
TABLE 79 US: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 80 US: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 81 US: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 82 US: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 145
TABLE 83 US: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146
TABLE 84 US: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 85 US: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146
TABLE 86 US: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 147
11.2.2 CANADA 147
11.2.2.1 Increasing incidence of bloodstream infections to drive market 147
TABLE 87 CANADA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 147
TABLE 88 CANADA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 148
TABLE 89 CANADA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 90 CANADA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 148
TABLE 91 CANADA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 92 CANADA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 93 CANADA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149
TABLE 94 CANADA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 150
TABLE 95 CANADA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 96 CANADA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 150
11.2.3 NORTH AMERICA: RECESSION IMPACT 151
11.3 EUROPE 151
TABLE 97 EUROPE: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 152
TABLE 98 EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 152
TABLE 99 EUROPE: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 152
TABLE 100 EUROPE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 101 EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 102 EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 153
TABLE 103 EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 104 EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 154
TABLE 105 EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 106 EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 107 EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 155
11.3.1 GERMANY 155
11.3.1.1 Germany commanded largest share of European blood culture tests market in 2022 155
TABLE 108 GERMANY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 156
TABLE 109 GERMANY: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 110 GERMANY: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 111 GERMANY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 112 GERMANY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 113 GERMANY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 114 GERMANY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 158
TABLE 115 GERMANY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 158
TABLE 116 GERMANY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158
TABLE 117 GERMANY: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 159
11.3.2 UK 159
11.3.2.1 High burden of sepsis and increased geriatric population to drive market 159
TABLE 118 UK: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 160
TABLE 119 UK: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 160
TABLE 120 UK: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 121 UK: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 122 UK: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 123 UK: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 161
TABLE 124 UK: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 162
TABLE 125 UK: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 126 UK: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 162
TABLE 127 UK: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 163
11.3.3 FRANCE 163
11.3.3.1 Rising geriatric population and favorable government regulations to drive market 163
TABLE 128 FRANCE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 163
TABLE 129 FRANCE: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 164
TABLE 130 FRANCE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 131 FRANCE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 164
TABLE 132 FRANCE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 133 FRANCE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 165
TABLE 134 FRANCE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165
TABLE 135 FRANCE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 166
TABLE 136 FRANCE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 166
TABLE 137 FRANCE: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 166
11.3.4 ITALY 167
11.3.4.1 Slow growth in healthcare sector with increased health expenditure to limit market 167
TABLE 138 ITALY: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 167
TABLE 139 ITALY: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 167
TABLE 140 ITALY: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 141 ITALY: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 142 ITALY: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 168
TABLE 143 ITALY: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 144 ITALY: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 169
TABLE 145 ITALY: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 169
TABLE 146 ITALY: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 170
TABLE 147 ITALY: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 170
11.3.5 SPAIN 170
11.3.5.1 Rapid increase in diagnostic procedures and improved healthcare infrastructure to drive market 170
TABLE 148 SPAIN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 171
TABLE 149 SPAIN: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 171
TABLE 150 SPAIN: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 171
TABLE 151 SPAIN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 152 SPAIN: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 153 SPAIN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 154 SPAIN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 173
TABLE 155 SPAIN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 173
TABLE 156 SPAIN: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 173
TABLE 157 SPAIN: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 174
11.3.6 REST OF EUROPE 174
TABLE 158 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 174
TABLE 159 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 175
TABLE 160 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 161 REST OF EUROPE: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 162 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 163 REST OF EUROPE: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 164 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 176
TABLE 165 REST OF EUROPE: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 177
TABLE 166 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 167 REST OF EUROPE: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 177
11.3.7 EUROPE: RECESSION IMPACT 178
11.4 ASIA PACIFIC 178
FIGURE 30 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET SNAPSHOT 179
TABLE 168 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 169 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 180
TABLE 170 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180
TABLE 171 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 172 ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 173 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 181
TABLE 174 ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 175 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 182
TABLE 176 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 182
TABLE 177 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 183
TABLE 178 ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 183
11.4.1 JAPAN 183
11.4.1.1 Japan to be largest market for blood culture tests in Asia Pacific 183
TABLE 179 JAPAN: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 184
TABLE 180 JAPAN: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 184
TABLE 181 JAPAN: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 182 JAPAN: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 183 JAPAN: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 185
TABLE 184 JAPAN: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 185 JAPAN: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
TABLE 186 JAPAN: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 186
TABLE 187 JAPAN: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187
TABLE 188 JAPAN: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 187
11.4.2 CHINA 187
11.4.2.1 Rapid economic growth and rising disposable income of middle-class population to drive market 187
TABLE 189 CHINA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 188
TABLE 190 CHINA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 188
TABLE 191 CHINA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 192 CHINA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 193 CHINA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 194 CHINA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 189
TABLE 195 CHINA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 190
TABLE 196 CHINA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 190
TABLE 197 CHINA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190
TABLE 198 CHINA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 191
11.4.3 INDIA 191
11.4.3.1 Rising prevalence of infectious diseases and growing geriatric population to drive market 191
TABLE 199 INDIA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 192
TABLE 200 INDIA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 192
TABLE 201 INDIA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 202 INDIA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 203 INDIA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 204 INDIA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 193
TABLE 205 INDIA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 194
TABLE 206 INDIA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 207 INDIA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 194
TABLE 208 INDIA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 195
11.4.4 REST OF ASIA PACIFIC 195
TABLE 209 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 195
TABLE 210 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196
TABLE 211 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 212 REST OF ASIA PACIFIC: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 196
TABLE 213 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 214 REST OF ASIA PACIFIC: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 197
TABLE 215 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 197
TABLE 216 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 217 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 198
TABLE 218 REST OF ASIA PACIFIC: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 198
11.4.5 ASIA PACIFIC: RECESSION IMPACT 199
11.5 LATIN AMERICA 199
11.5.1 FAVORABLE GOVERNMENT INITIATIVES TO DRIVE MARKET 199
11.5.2 LATIN AMERICA: RECESSION IMPACT 200
TABLE 219 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 200
TABLE 220 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 200
TABLE 221 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 222 LATIN AMERICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 223 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 224 LATIN AMERICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 225 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 202
TABLE 226 LATIN AMERICA: BLOOD CULTURE TESTS MARKET FOR MOLECULAR TECHNOLOGIES, BY TYPE, 2021–2028 (USD MILLION) 202
TABLE 227 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
TABLE 228 LATIN AMERICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 203
11.6 MIDDLE EAST & AFRICA 203
11.6.1 INFRASTRUCTURAL DEVELOPMENTS AND ADVANCED HEALTHCARE FACILITIES TO DRIVE MARKET 203
11.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 204
TABLE 229 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY METHOD, 2021–2028 (USD MILLION) 204
TABLE 230 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 204
TABLE 231 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR CONSUMABLES, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 232 MIDDLE EAST & AFRICA: BLOOD CULTURE MEDIA MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 233 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET FOR INSTRUMENTS, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 234 MIDDLE EAST & AFRICA: SUPPORTING LABORATORY EQUIPMENT MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 235 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 206
TABLE 236 MIDDLE EAST & AFRICA: MOLECULAR TECHNOLOGIES MARKET, BY TYPE, 2021–2028 (USD MILLION) 206
TABLE 237 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 238 MIDDLE EAST & AFRICA: BLOOD CULTURE TESTS MARKET, BY END USER, 2021–2028 (USD MILLION) 207

12 COMPETITIVE LANDSCAPE 208
12.1 MARKET OVERVIEW 208
TABLE 239 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN BLOOD CULTURE TESTS MARKET 208
12.2 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 210
FIGURE 31 BLOOD CULTURE TESTS MARKET: REVENUE SHARE ANALYSIS OF MAJOR PLAYERS 211
12.3 MARKET SHARE ANALYSIS 211
FIGURE 32 BLOOD CULTURE TESTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2022) 212
TABLE 240 BLOOD CULTURE TESTS MARKET: DEGREE OF COMPETITION 212
12.4 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 213
12.4.1 STARS 213
12.4.2 EMERGING LEADERS 213
12.4.3 PERVASIVE PLAYERS 214
12.4.4 PARTICIPANTS 214
FIGURE 33 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022) 214
12.5 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 215
12.5.1 PROGRESSIVE COMPANIES 215
12.5.2 STARTING BLOCKS 215
12.5.3 RESPONSIVE COMPANIES 215
12.5.4 DYNAMIC COMPANIES 215
FIGURE 34 BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 216
12.6 COMPANY FOOTPRINT 216
TABLE 241 BLOOD CULTURE TESTS MARKET: COMPANY FOOTPRINT ANALYSIS 217
12.6.1 METHOD FOOTPRINT 218
TABLE 242 BLOOD CULTURE TESTS MARKET: METHOD FOOTPRINT ANALYSIS 218
12.6.2 PRODUCT FOOTPRINT 219
TABLE 243 BLOOD CULTURE TESTS MARKET: PRODUCT FOOTPRINT ANALYSIS 219
12.6.3 TECHNOLOGY FOOTPRINT 220
TABLE 244 BLOOD CULTURE TESTS MARKET: TECHNOLOGY FOOTPRINT ANALYSIS 220
12.6.4 APPLICATION FOOTPRINT 221
TABLE 245 BLOOD CULTURE TESTS MARKET: APPLICATION FOOTPRINT ANALYSIS 221
12.6.5 END USER FOOTPRINT 222
TABLE 246 BLOOD CULTURE TESTS MARKET: END USER FOOTPRINT ANALYSIS 222
12.6.6 REGIONAL FOOTPRINT 223
TABLE 247 BLOOD CULTURE TESTS MARKET: REGIONAL FOOTPRINT ANALYSIS 223
12.7 COMPETITIVE SCENARIOS AND TRENDS 224
12.7.1 KEY PRODUCT LAUNCHES AND APPROVALS 224
TABLE 248 KEY PRODUCT LAUNCHES AND APPROVALS (JANUARY 2020–JULY 2023) 224
12.7.2 KEY DEALS 226
TABLE 249 KEY DEALS (JANUARY 2020–JULY 2023) 226
13 COMPANY PROFILES 228
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
13.1 KEY PLAYERS 228
13.1.1 BECTON, DICKINSON AND COMPANY 228
TABLE 250 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 228
FIGURE 35 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 229
13.1.2 BIOMÉRIEUX 233
TABLE 251 BIOMÉRIEUX: COMPANY OVERVIEW 233
FIGURE 36 BIOMÉRIEUX: COMPANY SNAPSHOT (2022) 234
13.1.3 THERMO FISHER SCIENTIFIC INC. 237
TABLE 252 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 237
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 238
13.1.4 DANAHER 241
TABLE 253 DANAHER: COMPANY OVERVIEW 241
FIGURE 38 DANAHER: COMPANY SNAPSHOT (2022) 242
13.1.5 LUMINEX CORPORATION 245
TABLE 254 LUMINEX CORPORATION: COMPANY OVERVIEW 245
FIGURE 39 LUMINEX CORPORATION: COMPANY SNAPSHOT (2022) 246
13.1.6 BRUKER 248
TABLE 255 BRUKER: COMPANY OVERVIEW 248
FIGURE 40 BRUKER: COMPANY SNAPSHOT (2022) 249
13.1.7 ROCHE DIAGNOSTICS 251
TABLE 256 ROCHE DIAGNOSTICS: COMPANY OVERVIEW 251
FIGURE 41 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2022) 252
13.1.8 IRIDICA 254
TABLE 257 IRIDICA: COMPANY OVERVIEW 254
FIGURE 42 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 255
13.1.9 T2 BIOSYSTEMS, INC. 256
TABLE 258 T2 BIOSYSTEMS, INC.: COMPANY OVERVIEW 256
FIGURE 43 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2022) 257
13.1.10 BINDER GMBH 258
TABLE 259 BINDER GMBH: COMPANY OVERVIEW 258
13.1.11 BIOBASE BIOTECH (JINAN) CO., LTD. 259
TABLE 260 BIOBASE BIOTECH (JINAN) CO., LTD.: COMPANY OVERVIEW 259
13.1.12 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD. 260
TABLE 261 SCENKER BIOLOGICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 260
13.1.13 BULLDOG BIO 262
TABLE 262 BULLDOG BIO: COMPANY OVERVIEW 262
13.1.14 ANAEROBE SYSTEMS, INC. 263
TABLE 263 ANAEROBE SYSTEMS, INC.: COMPANY OVERVIEW 263
13.1.15 HIMEDIA LABORATORIES PVT. LTD. 264
TABLE 264 HIMEDIA LABORATORIES PVT. LTD.: COMPANY OVERVIEW 264
13.1.16 AUTOBIO DIAGNOSTICS CO., LTD. 265
TABLE 265 AUTOBIO DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW 265
13.1.17 AXIOM LABORATORIES 266
TABLE 266 AXIOM LABORATORIES: COMPANY OVERVIEW 266
13.1.18 MIKROSCAN TECHNOLOGIES, INC. 267
TABLE 267 MIKROSCAN TECHNOLOGIES, INC.: COMPANY OVERVIEW 267
13.1.19 LABOTRONICS LTD. 269
TABLE 268 LABOTRONICS LTD.: COMPANY OVERVIEW 269
13.1.20 HARDY DIAGNOSTICS 270
TABLE 269 HARDY DIAGNOSTICS: COMPANY OVERVIEW 270
13.2 OTHER PLAYERS 271
13.2.1 OPGEN, INC. 271
13.2.2 MEDITECH TECHNOLOGIES INDIA PRIVATE LIMITED 271
13.2.3 CARL ZEISS AG 272
13.2.4 NIKON CORPORATION 273
13.2.5 TERUMO CORPORATION 273
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
14 APPENDIX 274
14.1 DISCUSSION GUIDE 274
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 279
14.3 CUSTOMIZATION OPTIONS 281
14.4 RELATED REPORTS 281
14.5 AUTHOR DETAILS 282